Yayın:
Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorZehra Sucuoğlu İşleyen
dc.contributor.authorŞaban Seçmeler
dc.contributor.authorAbdullah Sakin
dc.contributor.authorŞener CİHAN
dc.contributor.authorMehmet Beşiroğlu
dc.contributor.authorSeda Kahraman
dc.contributor.authorMelek Karakurt Eryılmaz
dc.contributor.authorEsra Zeynelgil
dc.contributor.authorEda Çalışkan Yıldırım
dc.contributor.authorEngin Kut
dc.contributor.authorNilay Şengül
dc.contributor.authorFatma Paksoy Türköz
dc.contributor.authorOzkan Alan
dc.contributor.authorÖzlem Özkul
dc.contributor.authorSelver Işık
dc.contributor.authorFeride Yılmaz
dc.contributor.authorAhmet Gülmez
dc.contributor.authorSema Türker
dc.contributor.authorGökhan Karakaya
dc.contributor.authorMeral Günaldı
dc.contributor.authorLeyla Özer
dc.contributor.authorAsude Aksoy
dc.contributor.authorFatih Karataş
dc.contributor.authorTeoman Şakalar
dc.contributor.authorDerya Demirtas Esmer
dc.contributor.authorFatih Teker
dc.contributor.authorNecla Demir
dc.contributor.authorÖzgecan Dülgar
dc.contributor.authorSerdar Turhal
dc.contributor.authorHacı Mehmet Türk
dc.contributor.authorKayhan Ertürk
dc.contributor.authorEmir Çelik
dc.contributor.authorM. Mustafa Atcı
dc.contributor.orcid0000-0002-5328-6554
dc.contributor.orcid0000-0003-2597-5931
dc.contributor.orcid0000-0001-7200-9440
dc.contributor.orcid0000-0003-0785-0238
dc.contributor.orcid0000-0002-2726-1740
dc.contributor.orcid0000-0002-3353-344X
dc.contributor.orcid0000-0001-9040-7266
dc.contributor.orcid0000-0002-7970-307X
dc.contributor.orcid0000-0002-5496-9824
dc.contributor.orcid0000-0002-5609-9658
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0001-7871-9566
dc.contributor.orcid0000-0003-4693-6587
dc.contributor.orcid0000-0003-0927-6962
dc.contributor.orcid0000-0003-2206-8148
dc.contributor.orcid0000-0001-5804-6800
dc.date.accessioned2026-05-20T10:18:14Z
dc.date.issued2026-02-14
dc.identifier.doi10.1186/s12885-026-15725-9
dc.identifier.issn1471-2407
dc.identifier.issue1
dc.identifier.openalexW7128928754
dc.identifier.urihttps://hdl.handle.net/11421/39734
dc.identifier.urihttps://doi.org/10.1186/s12885-026-15725-9
dc.identifier.volume26
dc.language.isoen
dc.relation.ispartofBMC Cancer
dc.rightsopenAccess
dc.subjectTolerability
dc.subjectSurgical oncology
dc.subjectTurkish
dc.subjectRegimen
dc.subjectMulticenter study
dc.subjectDisease
dc.subjectOverall survival
dc.subject.sdg3
dc.titleEvaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study
dspace.entity.typePublication

Dosyalar

Koleksiyonlar

Publications